Latest Information Update: 21 Jan 1997
At a glance
- Originator Unknown
- Developer Merckle
- Class Anticoagulants; Antithrombotics; Low molecular weight heparins
- Mechanism of Action Thrombin inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Thrombosis
Most Recent Events
- 21 Jan 1997 Investigation in Thrombosis in Germany (Unknown route)
- 15 Oct 1996 Preclinical development for Thrombosis in Germany (Unknown route)